Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02233322 · ClinicalTrials.gov registry record · NA
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02233322 is a NA study that has completed, run by Indiana University. The registered enrollment target is 8 participants.
The verdict
NCT02233322, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed legs in children) or bone pain and weakness in adults. This study is to test whether or not giving iron helps correct the high FGF23 and there by correcting the phosphate problem.
Interventions
- DIETARY_SUPPLEMENT Iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-11-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02233322
The ClinicalTrials.gov registry entry for NCT02233322 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iron is the first listed.
NCT02233322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02233322 about?
NCT02233322 is a clinical study titled "Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.". The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus...
What is the current status of trial NCT02233322?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2014-08. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT02233322?
The interventions under investigation include: Iron (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02233322?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.